Journal of Adolescent Health
Volume 45, Issue 5 , Pages 438-444, November 2009

Availability of Human Papillomavirus Vaccine at Medical Practices in an Area with Elevated Rates of Cervical Cancer

  • Sami L. Gottlieb, M.D., M.S.P.H.

      Affiliations

    • Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia
    • Corresponding Author InformationAddress correspondence to: Sami L. Gottlieb, M.D., M.S.P.H., Division of STD Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS E-02, Atlanta, GA 30333.
  • ,
  • Noel T. Brewer, Ph.D.

      Affiliations

    • UNC Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina
  • ,
  • Jennifer S. Smith, Ph.D.

      Affiliations

    • UNC Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina
  • ,
  • Katie M. Keating, M.P.H.

      Affiliations

    • UNC Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina
  • ,
  • Lauri E. Markowitz, M.D.

      Affiliations

    • Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia

Received 24 November 2008; accepted 28 May 2009. published online 22 July 2009.

Abstract 

Purpose

To assess availability of human papillomavirus (HPV) vaccine at medical practices in an area with elevated cervical cancer rates.

Methods

During July–November 2007, we conducted a telephone survey of staff at medical practices providing outpatient care to 9- to 26-year-old females in four North Carolina counties with elevated cervical cancer rates. We assessed availability of HPV vaccine and concerns about its provision.

Results

Staff from 71 of 96 eligible practices completed a full interview. Overall, 62% of these practices had HPV vaccine available to patients (family practice, 74%; pediatrics, 75%; obstetrics–gynecology, 64%; internal medicine, 15%). In multivariate analysis, practice characteristics that independently predicted a lower likelihood of carrying HPV vaccine were having at least 50% African-American patient population (odds ratio [OR] 0.19, 95% confidence interval [CI] 0.06–0.63) and providing only privately purchased (and no state-supplied) vaccines (OR 0.19, 95% CI 0.06–0.63). HPV vaccine nonproviders were significantly more likely than HPV vaccine providers to report “large” concerns about the up-front costs of purchasing HPV vaccine (52% vs. 27%, p < .05) and late reimbursement (33% vs. 14%, p < .05).

Conclusions

Approximately 1 year after its introduction, HPV vaccine was available at three-quarters of family practice and pediatrics practices, two-thirds of obstetrics–gynecology practices, and few internal medicine practices in an area with elevated cervical cancer rates. Practices' concerns about cost and reimbursement have implications for accessibility of HPV vaccine to those who need it most.

Keywords: Human papillomavirus, HPV vaccines, Adolescent health services

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1054-139X(09)00212-2

doi:10.1016/j.jadohealth.2009.05.013

Refers to article:

  • Vaccinating Adolescents—New Evidence of Challenges and Opportunities

    Lance E. Rodewald, Walter A. Orenstein
    Journal of Adolescent Health November 2009 (Vol. 45, Issue 5, Pages 427-429)

Journal of Adolescent Health
Volume 45, Issue 5 , Pages 438-444, November 2009